E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
The trial will be performed in 32 healthy subjects and in 60 patients with a liver disease subjected to MR imaging |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 8.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10028049 |
E.1.2 | Term | MRI |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess the hepatic uptake of Primovist® after intravenous administration of 25 µmol/kg body weight in 32 healthy volunteers and in 60 patients with a liver disease in dependence on the OATP1B1-genotype |
|
E.2.2 | Secondary objectives of the trial | |
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Inclusion criteria – healthy volunteers * age: 18 - 45 years * sex: male and female * ethnic origin: white * body weight: 19 kg/m² and 27 kg/m² * good health as evidenced by the results of the clinical examination, ECG, and the laboratory check-up, which are judged by the clinical investigator not to differ in a clinical relevant way from the normal state * written informed consent
Inclusion criteria – patients * age: 18 - 65 years * sex: male and female * ethnic origin: white * any liver disease (e.g. primary liver tumor, metastatic liver disease, liver cirrhosis, steatosis hepatis) which is subjected to MRI diagnostics * written informed consent
|
|
E.4 | Principal exclusion criteria |
Exclusion criteria – healthy volunteers • weight less than 45 kg • claustrophobia • cardiac pacemakers, metallic implants or metal-containing tatoos • history of allergic reactions • known hypersensitivity to the study medication or to their adjuvants • existing cardiac or hematological diseases and/or pathological findings, which might interfere with the drug's safety, tolerability and/or pharmacokinetics • existing hepatic and renal diseases and/or pathological findings, which might interfere with the drug's safety, tolerability and/or pharmacokinetics • existing gastrointestinal diseases and/or pathological findings, which might interfere with the drug's safety, tolerability and/or pharmacokinetics • acute or chronic diseases which could affect drug metabolism or elimination • history of any serious psychological disorder • drug or alcohol dependence • positive drug or alcohol screening • smokers of 10 or more cigarettes per day • positive anti-HIV-test, HBs-Ag-test or anti-HCV-test • volunteers who are on a diet which could affect the pharmacokinetics of the drug • heavy tea or coffee drinkers (more than 1L per day) • lactation and pregnancy test positive or not performed • volunteers suspected or known not to follow instructions • volunteers who are unable to understand the written and verbal instructions, in particular regarding the risks and inconveniences they will be exposed to as a result of their participation in the study • volunteers liable to orthostatic dysregulation, fainting, or blackouts • participation in a clinical trial during the last 3 months prior to the start of the study • less than 14 days after last acute disease • any systemically available medication within 4 weeks prior to the intended first administration unless because of the terminal elimination half-life complete elimination from the body can be assumed for the drug and/or its primary metabolites (except oral contraceptives) • repeated use of drugs during the last 4 weeks prior to the intended first administration, which can influence hepatic biotransformation (e.g. barbiturates, cimetidine, phenytoin, rifampicin) • intake of grapefruit containing food or beverages within 7 days prior to administration
5.4 Exclusion criteria – patients • weight less than 45 kg • claustrophobia • cardiac pacemakers, metallic implants or metal-containing tatoos • history of allergic reactions • known hypersensitivity to the study medication or to their adjuvants • acute bleedings within the last two weeks, elevated risk of acute bleedings (ulcer, oesophageal varicosis, regular intake of coumarines) or subnormal haemoglobin value • patients who are unable to understand the written and verbal instructions, in particular regarding the risks and inconveniences they will be exposed to as a result of their participation in the study • patients liable to orthostatic dysregulation, fainting, or blackouts • lactation and pregnancy test positive or not performed • repeated use of drugs during the last 4 weeks prior to the intended first administration, which can influence hepatic biotransformation (e.g. barbiturates, cimetidine, phenytoin, rifampicin) • intake of grapefruit containing food or beverages within 7 days prior to administration
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
pharmacokinetic characteristics of Gd-EOB-DTPA;
signal intensity of liver, gallbladder and background noise
calculation of the signal-to-noise ratio and of the percentage of enhancement of the signal intensities (percentage of average accumulation) after drug injection
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | Yes |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Yes |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | Yes |
E.7.1.3.1 | Other trial type description |
|
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | Information not present in EudraCT |
E.8.1.2 | Open | Information not present in EudraCT |
E.8.1.3 | Single blind | Information not present in EudraCT |
E.8.1.4 | Double blind | Information not present in EudraCT |
E.8.1.5 | Parallel group | Information not present in EudraCT |
E.8.1.6 | Cross over | Information not present in EudraCT |
E.8.1.7 | Other | Information not present in EudraCT |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 7 |
E.8.9.1 | In the Member State concerned days | 0 |